Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

DALY II USA/ MB-CART2019.1 for DLBCL

ClinicalTrials.gov ID: NCT04792489

Public ClinicalTrials.gov record NCT04792489. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymphoma (DLBCL) after receiving at least 2 lines of therapy, primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL) after receiving at least one line of therapy, mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy, and DLBCL transplant-ineligible after receiving at least one line of therapy.

Study identification

NCT ID
NCT04792489
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Miltenyi Biomedicine GmbH
Industry
Enrollment
315 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 24, 2021
Primary completion
Dec 30, 2026
Completion
Dec 30, 2028
Last update posted
Jul 12, 2026

2021 – 2028

United States locations

U.S. sites
30
U.S. states
24
U.S. cities
29
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233 Recruiting
Banner MD Anderson Cancer Center Gilbert Arizona 85234 Recruiting
Mayo Clinic Phoenix Arizona 85054 Recruiting
UC San Diego Health La Jolla California 92037 Recruiting
Stanford University Stanford California 94305 Recruiting
Colorado Blood Cancer Institute Denver Colorado 80218 Recruiting
Yale University New Haven Connecticut 06520 Recruiting
Baptist Health Miami Cancer Institute Miami Florida 33176 Recruiting
Winship Cancer Institute of Emory University Atlanta Georgia 30322 Recruiting
Georgia Cancer Center at Augusta University Augusta Georgia 30912 Recruiting
Robert H Lurie Cancer Center Chicago Illinois 60611 Recruiting
University of Kansas Cancer Center Westwood Kansas 66205 Recruiting
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center Baltimore Maryland 21201 Recruiting
Dana Farber Cancer Institute Boston Massachusetts 02215 Recruiting
University of Michigan Ann Arbor Michigan 48109 Recruiting
Mayo Clinic Rochester Minnesota 55905 Recruiting
Washington University, St. Louis St Louis Missouri 63110 Recruiting
University of Nebraska Medical Center Omaha Nebraska 68198 Terminated
Memorial Sloan Kettering Cancer Center New York New York 10065 Recruiting
Duke University Medical Center - Division of Hematologic Malignancies Durham North Carolina 27705 Recruiting
The Ohio State University Wexner Medical Center James Cancer Columbus Ohio 43210 Recruiting
Oregon Health and Science University Knight Cancer Institute Portland Oregon 97239 Recruiting
Allegheny Health Network Cancer Institute Pittsburgh Pennsylvania 15212 Recruiting
University of Pittsburgh - Hillman Cancer Center Pittsburgh Pennsylvania 15260 Withdrawn
SCRI Oncology Partners Nashville Tennessee 37203 Recruiting
UT Southwestern Medical Center Dallas Texas 75390 Recruiting
The University of Texas MD Anderson Cancer Center Houston Texas 77030 Recruiting
Texas Transplant Institute San Antonio Texas 98109 Recruiting
Fred Hutchinson Cancer Center Seattle Washington 98109 Recruiting
Froedtert Hospital and the Medical College of Wisconsin Milwaukee Wisconsin 53226 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04792489, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 12, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04792489 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →